Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00051909
First received: January 17, 2003
Last updated: July 18, 2006
Last verified: July 2006

January 17, 2003
July 18, 2006
November 2002
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00051909 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Alzheimer's Disease
Drug: LY451395
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
June 2003
Not Provided

Inclusion Criteria:

  • Must have a clinical diagnosis of Alzheimer's Disease
  • Must be at least 50 years of age
  • Must fluently read and speak English
  • Must have a reliable caregiver

Exclusion Criteria:

  • Has serious health problems other than Alzheimer's Disease
  • Cannot swallow whole pills
  • Has had a menstrual period in the last two years
  • Takes insulin for diabetes
  • Has taken Aricept, Reminyl, or Exelon in the last 5 weeks
Both
50 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00051909
6764, H6N-MC-LEAM
Not Provided
Not Provided
Eli Lilly and Company
Not Provided
Not Provided
Eli Lilly and Company
July 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP